TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Rhea-AI Summary

TScan Therapeutics (Nasdaq: TCRX) will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on Wednesday, November 12, 2025 at 10:00 a.m. ET at the InterContinental Boston.

A live webcast will be available in the company’s Events and Presentations section at ir.tscan.com, and an archived replay will remain on the site for 90 days after the event.

News Market Reaction

+1.34%

1 alert

+1.34% News Effect

+$870K Valuation Impact

$66M Market Cap

0.9x Rel. Volume

On the day this news was published, TCRX gained 1.34%, reflecting a mild positive market reaction. This price movement added approximately $870K to the company's valuation, bringing the market cap to $66M at that time.

Data tracked by StockTitan Argus on the day of publication.

WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the Guggenheim 2^nd Annual Healthcare Innovation Conference being held at the InterContinental Boston in Boston, MA on Wednesday, November 12, 2025 at 10:00 a.m. Eastern Time.

A webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website for 90 days following the event.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidate is in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA^™ Phase 1 heme trial). The Company has developed multiple TCR-T therapy candidates for solid tumors and is currently developing methods for in vivo engineering using these candidates. The Company is also applying their TargetScan platform to discover novel targets in various T cell-mediated autoimmune diseases.

Contacts

Troy Neubecker
TScan Therapeutics, Inc.
Investor Relations
857-399-9517
tneubecker@tscan.com

Melissa Forst
Argot Partners
212-600-1902
TScan@argotpartners.com

FAQ

When will TScan Therapeutics (TCRX) present at the Guggenheim Healthcare Innovation Conference?

TScan will present in a fireside chat on November 12, 2025 at 10:00 a.m. ET.

How can investors watch TScan Therapeutics (TCRX) at the Guggenheim conference?

Investors can watch a live webcast via the Events and Presentations page at ir.tscan.com.

Will there be a replay of TScan Therapeutics (TCRX) webcast from the November 12, 2025 presentation?

Yes, an archived replay will be available on the company website for 90 days following the event.

What topics will TScan Therapeutics (TCRX) likely cover in the November 12, 2025 fireside chat?

The company will discuss its clinical-stage TCR-engineered T cell (TCR-T) therapies for cancer and recent program updates.

Where is the Guggenheim 2nd Annual Healthcare Innovation Conference taking place for TScan Therapeutics (TCRX)?

The conference is at the InterContinental Boston in Boston, MA.